Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma ...

Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients ...

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

The personalized cancer vaccine trial conducted by Yale University offers promising results for patients with advanced kidney ...

Lawmakers are weighing an exception to Iowa's statute of repose law for medical malpractice cases, which requires patients to sue within six years.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at A replay of the ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...